Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions
Cognitive inflexibility in schizophrenia is treatment-resistant and predictive of poor outcome. This study examined the effect of asenapine, a novel psychopharmacologic agent being developed for schizophrenia and bipolar disorder, on cognitive dysfunction in the rat.
The objective of this paper was to establish whether asenapine has a beneficial effect on the performance of rats with ibotenic acid-induced lesion of the medial prefrontal cortex (mPFC) in an intradimensional/extradimensional (ID/ED) test of cognitive flexibility.
The effect of subcutaneously administered asenapine (0.75, 7.5, 75 μg/kg) on ID/ED performance of controls or mPFC-lesioned rats was examined using a within-subjects, repeated-measures design. In a second experiment, lesioned and control rats were tested with or without asenapine in a modified version of the task, with multiple set-shifts, before brains were processed for Fos-immunoreactivity in the mPFC.
The mPFC lesion-induced deficit in the ID/ED task was stable with repeated testing over more than two months. Asenapine (75 μg/kg s.c., p < 0.05) completely restored the performance of lesioned rats. Experiment 2 replicated both lesion and asenapine effects and demonstrated that it is possible to measure set-shifting multiple times within a test session. Asenapine (75 μg/kg s.c.) was associated with differential activation of the neurons in the anterior mPFC of lesioned animals, but was without effect in controls.
Asenapine can ameliorate mPFC lesion-induced impairment in attentional set-shifting, and is associated with a greater activation of the spared neurons in the anterior mPFC. These data suggest that asenapine may benefit impaired cognitive flexibility in disorders such as schizophrenia.
KeywordsSchizophrenia ID/ED Attentional set-shifting Ibotenic acid
- Green MF, Kern RS, Braff DL, Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff?”. Schiz Bull 26:119–136Google Scholar
- Henry B, Grimwood S, de Greef HJMM, Shahid M (2008) Asenapine: a translational analysis of receptor occupancy in human and rat brain with therapeutic implications. Biol Psychiatry 63:104sGoogle Scholar
- Huang M, Li Z, Dai J, Shahid M, Wong EHF, Meltzer HY (2008) Asenapine increased dopamine, norepinephrine and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharm (advance online publication, 16 April 2008). doi:10.1038/npp.2008.20
- Jentsch JD, Shahid M, Wong EHF, Roth RH (2006) Asenapine improves cognitive function in monkeys repeatedly exposed to the psychotomimetic drug phencyclidine. Schiz Res 81:85(S)Google Scholar
- McIntyre R, Hirschfield R, Calabrese J, Panagides J, Szegedi A (2008) Asenapine in bipolar disorder: an overview of the clinical trials in the Olympia program. Int J Neuropsychopharmacol 11:183(S)Google Scholar
- Marcus M, Franberg O, Ivanov I, Shahid M, Svensson TH (2008) Asenapine activates cortical and subcortical catecholamine systems by different mechanisms. Int J Neuropsychopharmacol 11:260(S)Google Scholar
- Milner B (1963) Effect of different brain lesions on card sorting. Arch Neurol 9:90–100Google Scholar
- Neill JC, Shahid M, Grayson B, Marston HM, Snigdha S (2008) Asenapine improves a subchronic phencyclidine-induced deficit in object recognition memory in the rat. Biol Psychol 63:75S–76SGoogle Scholar
- Neill JC, Shahid M, Wong EHF, Idris NF (2006) Comparison of the efficacy of asenapine, risperidone, and olanzapine to improve a reversal learning deficit in the rat. Schizophr Res 81:s105–106Google Scholar
- Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates. Academic Press, San DiegoGoogle Scholar
- Shahid M, Summer BEH, Wong EHF, Henry B (2007) Asenapine displays distinctive induction patterns of c-fos mRNA expression in rat forebrain regions. Biol Psychiat 61:256(S)Google Scholar
- Shahid M, Walker GB, Zorn SH, Wong EH (2008) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol, 28 February. doi:10.1177/0269881107082944